2010•AIDSRequires access
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients
Aurélie Barrail‐Tran, Yazdan Yazdanpanah, Lauriane Goldwirt, Geneviève Chêne, Céline Colin, Christophe Piketty, Diane Bollens, Christine Katlama, Diane Descamps, Jean‐Michel Molina, Catherine Fagard, Anne‐Marie Taburet
Open publisher page 21 citations
Abstract
Etravirine is an enzyme inducer and could lower the concentration of combined drugs. Ten HIV-1-infected patients with multiple treatment failure received raltegravir (400 mg, twice daily) and darunavir/ritonavir (600/100 mg, twice daily). Addition of etravirine (200 mg, twice daily) leads to a significant increase in raltegravir and darunavir trough concentrations (405 vs. 118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine.